| Literature DB >> 33051335 |
Aénora Roger-Rollé1,2, Eve Cariou1,2, Khailène Rguez1,2, Pauline Fournier1,2, Yoan Lavie-Badie1,2,3, Virginie Blanchard1,2,3,4, Jérôme Roncalli1,4, Michel Galinier1,2,4, Didier Carrié1,2,4, Olivier Lairez5,2,3,4.
Abstract
BACKGROUND: Cardiac amyloidosis (CA) is a life-threatening restrictive cardiomyopathy. Identifying patients with a poor prognosis is essential to ensure appropriate care. The aim of this study was to compare myocardial work (MW) indices with standard echocardiographic parameters in predicting mortality among patients with CA.Entities:
Keywords: echocardiography; heart failure with preserved ejection fraction; restrictive cardiomyopathy
Mesh:
Year: 2020 PMID: 33051335 PMCID: PMC7555098 DOI: 10.1136/openhrt-2020-001346
Source DB: PubMed Journal: Open Heart ISSN: 2053-3624
Figure 1Seventeen-segment bull’s-eye representation of MW indices and GLS, and steps for MW indices analysis. GLS, global longitudinal strain; MW, myocardial work.
Baseline clinical, biological and electrocardiograms characteristics
| Overall population | AL (1) | Wild-type ATTR (2) | Variant-type ATTR (3) | P value | 1 versus 2 | Posthoc analysis | 3 versus 1 | |
| Baseline characteristic | ||||||||
| Age—years | 78±10 | 68±12 | 82±7 | 71±6 | <0.001 | <0.001 | <0.001 | 0.722 |
| Male gender, n (%) | 95 (81) | 18 (69) | 68 (85) | 9 (75) | 0.188 | . | ||
| Body mass index—kg/m2 | 25±3 | 24±3 | 26±3 | 26±2 | 0.116 | . | ||
| Systolic blood pressure—mm Hg | 131±20 | 120±19 | 134±20 | 139±17 | 0.010 | 0.010 | 0.260 | 0.007 |
| Diastolic blood pressure—mm Hg | 76±11 | 72±10 | 76±11 | 82±14 | 0.044 | 0.072 | 0.121 | 0.033 |
| Heart rate—bpm | 77±16 | 82±10 | 77±18 | 70±7 | 0.009 | 0.033 | 0.171 | <0.001 |
| Medical history, n (%) | ||||||||
| Current smoker | 1 (1) | 1 (4) | 0 | 0 | 0.170 | |||
| Hypertension | 58 (49) | 8 (31) | 45 (56) | 5 (42) | 0.069 | |||
| Dyslipidaemia | 35 (30) | 6 (23) | 26 (33) | 3 (25) | 0.617 | |||
| Diabetes | 13 (11) | 2 (8) | 11 (14) | 0 | 0.306 | |||
| Ischaemic heart disease | 25 (21) | 3 (12) | 22 (28) | 0 | 0.038 | 0.097 | 0.038 | 0.226 |
| NYHA class, n (%) | ||||||||
| NYHA 1 | 25 (21) | 5 (19) | 17 (21) | 3 (25) | 0.922 | |||
| NYHA 2 | 70 (59) | 15 (58) | 48 (60) | 7 (58) | 0.976 | |||
| NYHA 3 | 20 (17) | 5 (19) | 13 (16) | 2 (17) | 0.940 | |||
| NYHA 4 | 3 (3) | 1 (4) | 2 (3) | 0 | 0.784 | |||
| Medication, n (%) | ||||||||
| Diuretics | 76 (64) | 12 (46) | 60 (75) | 4 (33) | 0.002 | 0.006 | 0.004 | 0.463 |
| Tafamidis | 28 (24) | – | 20 (25) | 8 (67) | <0.001 | 0.004 | ||
| Biochemistry | ||||||||
| NT-proBNP—ng/L | 2423 (1105–4380) | 2108 (691–4645) | 2607 (1408–4675) | 1096 (221–3036) | 0.062 | |||
| Troponin—ng/L | 71±46 | 76±54 | 74±44 | 41±32 | 0.007 | 0.903 | 0.002 | 0.008 |
| eGFR—mL/min/1.73 m2 | 56±21 | 61±26 | 52±19 | 73±16 | 0.002 | 0.084 | 0.001 | 0.209 |
| ECG, n (%) | ||||||||
| Atrial fibrillation | 31 (26) | 2 (8) | 28 (35) | 1 (8) | 0.008 | 0.008 | 0.065 | 0.946 |
| Low voltage | 13 (11) | 8 (31) | 4 (5) | 1 (8) | 0.001 | <0.001 | 0.637 | 0.136 |
| Pseudo infarct pattern | 14 (12) | 4 (15) | 7 (9) | 3 (25) | 0.475 | |||
| Functional analysis | ||||||||
| Peak oxygen consumption—mL/min/kg | 15±5 | 16±5 | 14±5 | 17±6 | 0.087 | |||
Data are presented as number (percent), mean±SD if normally distributed or median (IQR) if not normally distribute.
AL, light chain amyloidosis; ATTR, transthyretin amyloidosis; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-hormone brain natriuretic peptide; NYHA, New York Heart Association.
Correlation between GWI, GWE, LVEF, GLS, MCF and clinical, biochemical and echocardiographic parameters
| GWI | GWE | GLS | LVEF | MCF | |
| Systolic blood pressure | R=0.543* | R=0.158 | R=0.280† | R=0.294† | R=0.164 |
| Functional status | |||||
| Peak oxygen consumption | R=0.359† | R=0.141 | R=0.313† | R=0.110 | R=0.168 |
| Biochemistry | |||||
| NT-proBNP | R=−0.518* | R=−0.383* | R=−0.553* | R=−0.382* | R=−0.336* |
| eGFR | R=0.309* | R=0.257† | R=0.345* | R=0.205† | R=0.203† |
| Troponin | R=−0.477* | R=−0.287† | R=−0.451* | R=−0.185 | R=−0.253† |
| Echocardiography | |||||
| LV stroke volume | R=0.488* | R=0.315† | R=0.511* | R=0.420* | R=0.792* |
| Left atrial volume index | R=−0.061 | R=−0.009 | R=−0.053 | R=−0.096 | R=−0.158 |
| E/A | R=−0.314† | R=0.033 | R=-.289† | R=−0.242† | R=−0.273† |
| E/e’ | R=−0.167 | R=−0.123 | R=−0.237† | R=−0.081 | R=−0.234† |
| LVEF | R=0.555* | R=0.384* | R=0.595* | – | R=0.530* |
| GLS | R=0.896* | R=0.642* | – | R=0.595* | R=0.567* |
| MCF | R=0.493* | R=0.326* | R=0.567* | R=0.530* | – |
| GWI | – | R=0.625* | R=0.896* | R=0.555* | R=0.336* |
| GWE | R=0.625* | – | R=0.642* | R=0.384* | R=0.493* |
*p<0.001.
†p <0.05.
eGFR, estimated glomerular filtration rate; GLS, global longitudinal strain; GWE, global work efficiency; GWI, global work index; LV, left ventricular; LVEF, left ventricular ejection fraction; MCF, myocardial contraction fraction; NT-proBNP, N-terminal pro-hormone brain natriuretic peptide.
Figure 2Correlation between GWI, GWE, LVEF, GLS, MCF and NT-proBNP. GLS, global longitudinal strain; GWE, global work efficiency; GWI, global work index; LVEF, left ventricular ejection fraction; MCF, myocardial contraction fraction; NT-proBNP, N-terminal pro-hormone brain natriuretic peptide.
Figure 3Correlation between GWI, GLS and peak oxygen consumption. GLS, global longitudinal strain; GWI, global work index.
Echocardiographic characteristics
| Interventricular wall thickness—mm | 17±3 | 15±2 | 18±3 | 17±4 | 0.007 | 0.002 | 0.310 | 0.170 |
| LVEF—% | 51±13 | 52±13 | 50±13 | 56±11 | 0.242 | |||
| LV stroke volume—mL | 50±19 | 50±20 | 50±19 | 52±18 | 0.825 | |||
| MCF—% | 19±9 | 22±12 | 17±9 | 21±9 | 0.094 | |||
| Left atrial volume index—mL/m2 | 43±15 | 38±13 | 45±14 | 43±23 | 0.078 | |||
| E wave—cm/s | 82±23 | 87±27 | 80±21 | 84±25 | 0.478 | |||
| A wave—cm/s | 59±31 | 71±38 | 53±26 | 63±29 | 0.129 | |||
| E/A | 1.5 (0.8–2.7) | 1.3 (0.7–2) | 1,8 (0.9–2.8) | 1 (0.9–1.6) | 0.324 | |||
| e’ wave—cm/s | 6±2 | 6±2 | 6±2 | 7±2 | 0.283 | |||
| E/e’ | 15±7 | 16±7 | 15±7 | 16±12 | 0.728 | |||
| Deceleration time—ms | 206±84 | 188±63 | 212±93 | 208±52 | 0.449 | |||
| GLS—% | 11±4 | 11±2 | 10±4 | 15±5 | 0.006 | 0.214 | 0.003 | 0.010 |
| Relative apical LS | 1.1 (0.9–1.4) | 1 (0.9–1.2) | 1.2 (0.9–1.5) | 0.9 (0.9–1) | 0.043 | 0.048 | 0.068 | 0.456 |
| GWI—mm Hg% | 1169±538 | 1094±422 | 1091±502 | 1755±730 | 0.012 | 0.840 | 0.004 | 0.010 |
| GWE—% | 87±8 | 89±8 | 86±8 | 91±5 | 0.049 | 0.053 | 0.066 | 0.741 |
| Global constructive work—mm Hg% | 1344±562 | 1225±406 | 1290±506 | 1965±822 | 0.013 | 0.654 | 0.005 | 0.008 |
| Global wasted work—mm Hg% | 120±100 | 101±95 | 128±106 | 107±68 | 0.241 | 0.090 | 0.772 | 0.442 |
Data are presented as number (percent), mean±SD if normally distributed or median (IQR) if not normally distributed.
AL, light chain amyloidosis; ATTR, transthyretin amyloidosis; GLS, global longitudinal strain; GWE, global work efficiency; GWI, global work index; LV, left ventricular; LVEF, LV ejection fraction; MCF, myocardial contraction fraction.
Figure 4Receiver operating characteristic curves comparing GWI, GWE, LVEF, GLS and MCF predicting mortality. AUC, area under the curve; GLS, global longitudinal strain; GWE, global work efficiency; GWI, global work index; LVEF, left ventricular ejection fraction; MCF, myocardial contraction fraction.
Performance of echocardiographic parameters to predict all-cause mortality
| Parameter | Cut-off value | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
| LVEF | 52% | 58 | 56 | 28 | 82 |
| MCF | 15% | 64 | 44 | 72 | 72 |
| GLS | −10% | 65 | 49 | 29 | 81 |
| GWI | 937 mm Hg/% | 65 | 48 | 29 | 81 |
| GWE | 89% | 64 | 81 | 35 | 87 |
GLS, global longitudinal strain; GWE, global work efficiency; GWI, global work index; LVEF, left ventricular ejection fraction; MCF, myocardial contraction fraction; NPV, negative predictive value; PPV, positive predictive value.